Related Experiment Videos
[Experience in using T-activin in multiple sclerosis patients].
Zhurnal Nevropatologii I Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia : 1952)
|January 1, 1984
Summary
T-activin (AFT-6 fraction) improved immune status in multiple sclerosis patients. Clinical benefits were most pronounced in those with secondary progressive multiple sclerosis.
Area of Science:
- Immunology
- Neurology
Context:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Current treatments aim to manage disease course and symptoms, but immunological modulation remains a key research area.
Purpose:
- To evaluate the immunocorrective effects of T-activin (AFT-6 fraction) in patients with multiple sclerosis.
- To assess the clinical and immunological responses to T-activin treatment across different MS disease courses.
Summary:
- Forty patients with varying multiple sclerosis courses received T-activin (AFT-6 fraction).
- Immunological status was monitored before, during, and after treatment.
- AFT-6 demonstrated a positive impact on the T-immunity system, normalizing lymphocyte counts and enhancing T-cell activity.
Impact:
- T-activin treatment showed good clinical response in patients with secondary progressive multiple sclerosis.
- Less prominent effects were observed in patients with prolonged progressive or stabilized disease stages with severe symptoms.
- The study highlights T-activin's potential as an immunomodulatory agent in managing multiple sclerosis, particularly for specific disease phenotypes.